Journal Management System
ScopeMed is an
Online Journal/Article Management system
that can enable all of the operations of
the editorial functions of a journal.
Home  |   Add your Journal  |   Features  |   Job Opportunities/Service Offers  |   Journal List
Author Login | Reviewer Login | Editor Login
Search  

Medical Archives
Periodical of AVICENA, d.o.o., Sarajevo
Journal Home Page
ISSN: 0350-199X (Print)
ISSN: 1986-5961 (Online)
Language: [ English ]  
News / Announcements

  » Volume 68, Issue 3
      pp. 156-222
  » Volume 68, Issue 2
      pp. 76-146
  » Volume 68, Issue 1
      pp. 4-70

 

Open Access

Original Research



The Efficacy of Levofloxacin-based Triple Therapy for First-line Helicobacter Pylori Eradication

Skender Telaku, Suzana Manxhuka-Kerliu, Bledar Kraja, Gentiana Qirjako, Skerdi Prifti, Hajrullah Fejza.

Abstract
Introduction: Because of the increasing resistance to clarithromycin and metronidazole, new therapeutic alternatives are needed. The purpose of this study was to compare the efficacy of 7- and 10-day triple therapy including omeprazole, levofloxacin and amoxicilline for Helicobacter pylori eradication as a first-line therapy. Methods: One hundred and five patients with peptic ulcer disease and with non-ulcer dyspepsia infected with Helicobacter pylori were included in this study. Patients were randomized to receive either 7-day or 10-day therapy with omeprazole (20 mg b.i.d.), plus levofloxacin (500 mg o.i.d.) and amoxicilline (1000 mg b.i.d.). Eradication was assessed by negative histological analyses, negative H. pylori stool antigen or rapid urease test. Results: In Group 1, the eradication rate was 86, 2%, while in group 2, eradication rate was 93, 6%. There was no difference between groups (p=0.218). Adverse effects were reported in 5, 25% of the patients, including nausea and diarrhea. Conclusions: The levofloxacin-based regimen can be one effective therapy for the first-line anti-H. pylori treatment. However, a levofloxacin-based triple therapy is not generally recommended as first-line therapy at the moment due to concerns about the rising prevalence of quinolone-resistant strains in the first-line and second-line anti-H. pylori therapies.

Key words: Helicobacter pylori, levofloxacin, first-line therapy


ARTICLE TOOLS
Abstract
PDF Fulltext
Print this article Print this Article
How to cite this articleHow to cite this article
Export to
Export to
Related Records
 Articles by Skender Telaku
Articles by Suzana Manxhuka-Kerliu
Articles by Bledar Kraja
Articles by Gentiana Qirjako
Articles by Skerdi Prifti
Articles by Hajrullah Fejza
on IndexScholar Fulltext
on Google
on Google Scholar
Article Statistics
 Viewed: 883
Downloaded: 422
(Last 7 Days: 4)
Cited: 0
Emailed: 0

REFERENCES
1. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007; 56: 772-781. http://dx.doi.org/10.1136/gut.2006.101634   [Pubmed]          [PMC Free Fulltext]    
 
2. Malfertheiner P, Megraud, F, O'Morain CA, Atherton J, Axon, AT, Bazzoli F, Gensini, GF, Gisbert JP, Graham DY, Rokkas T, El-Omar, EM, Kuipers, EJ. & European Helicobacter Study Group. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut. 2012; 61(5): 646-664. http://dx.doi.org/10.1136/gutjnl-2012-302084   [Pubmed]       
 
3. Ba-os F, Madridejos R, Cabezas C, et al. Effectiveness of omeprazole, clarithromycin and amoxycillin therapy to eradicate Helicobacter pylori in patients with active peptic ulcer. Preliminary results of GENPY study. Med Clin (Barc). 2000; 114: 441-443.
 
4. Palmas F, Pellicano R, Massimetti E, et al. Eradication of Helicobacter pylori infection with proton pump inhibitor based triple therapy. A randomized study. Panminerva Med. 2002; 44: 145-147.
 
5. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010; 59: 1143-1153. http://dx.doi.org/10.1136/gut.2009.192757   [Pubmed]       
 
6. Telaku S, Zeka S, Veliu A, Manxhuka-Kerliu S, et al. Comparison of one week and two weeks of triple therapy for the eradication of Helicobacter pylori in Kosovo. Turk J Gastroenterol. 2006; 15(1): PB02/4.
 
7. Sanchez JE, Saenz NG, Rincon MR, et al. Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones. J Antimicrob Chemother. 2000; 46: 283-285. http://dx.doi.org/10.1093/jac/46.2.283   [Pubmed]       
 
8. Tanaka M, Isogai E, Isogai H, et al. Synergic effect of quinolone antibacterial agents and proton pump inhibitors on Helicobacter pylori. J Antimicrob Chemother. 2002; 49: 1039-1040. http://dx.doi.org/10.1093/jac/dkf055   [Pubmed]       
 
9. Sprandel KA, Rodvold KA. Safety and tolerability of fluoroquinolones. Clin Cornerstone. 2003; Suppl 3: S29-36.
 
10. Edlund C, Nord CE. Effect of quinolones on intestinal ecology. Drugs. 1999; Suppl 2: 65–70.
 
11. Antos D, Schneider-Brachert W, Bästlein E, et al. 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicilline, and high-dose esomeprazole in patients with known antimicrobial sensitivity. Helicobacter. 2006; 11: 39-45. http://dx.doi.org/10.1111/j.0083-8703.2006.00375.x   [Pubmed]       
 
12. Cammarota G, Cianci R, Cannizzaro O, et al. Efficacy of two one-week rabeprazole/ levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther. 2000; 14: 1339-1343. http://dx.doi.org/10.1046/j.1365-2036.2000.00846.x   [Pubmed]       
 
13. Di Caro S, Zocco MA, Cremonini F, et al. Levofloxacin based regimens for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol. 2002; 14: 1309-1312. http://dx.doi.org/10.1097/00042737-200212000-00004   [Pubmed]       
 
14. Gisbert JP, Fernández-Bermejo M, Molina-Infante J, et al. First-line triple therapy with levofloxacin for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2007; 26: 495-500. http://dx.doi.org/10.1111/j.1365-2036.2007.03384.x   [Pubmed]       
 
15. Nista EC, Candelli M, Zocco MA, et al. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol. 2006; 101: 1985-1990. http://dx.doi.org/10.1111/j.1572-0241.2006.00716.x   [Pubmed]       
 
16. Schrauwen RW, Janssen MJ, de Boer WA. Seven-day PPI triple therapy with levoflo-xacin is very effective for Helicobacter pylori eradication. Neth J Med. 2009; 67: 96-101.
 
17. Marzio L, Coraggio D, Capodicasa S, Grossi L, Cappello G. Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicilline, and esomeprazole. Helicobacter. 2006; 11: 237-242. http://dx.doi.org/10.1111/j.1523-5378.2006.00407.x   [Pubmed]       
 
18. Antonio Cuadrado-Lavín, J. Ramón Salcines-Caviedes, Miguel F. Carrascosa, et al.
 
19. Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trial. J Antimicrob Chemother. 2012; 67: 2254-2259. http://dx.doi.org/10.1093/jac/dks209   [Pubmed]       
 
20. Seven G, Cinar K, Yakut M, Idilman R, Ozden A. Assessment of Helicobacter pylori eradication rate of triple combination therapy containing levofloxacin. Turk J Gastro-enterol. 2011; 22(6): 582-586.
 
21. Iacopini, F, Crispino, P, Paoluzi OA, Consolazio A, Pica R, Rivera M. et al. One-week once daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for Helicobacter pylori eradication. Dig Liver Dis 2005; 37: 571-576. http://dx.doi.org/10.1016/j.dld.2005.03.007   [Pubmed]       
 
22. Rispo A, Di Girolamo E, Cozzolino A, Bozzi R, Morante A, Pasquale L. Levofloxacin in first-line treatment of Helicobacter pylori infection. Helicobacter. 2007; 12: 364-365. http://dx.doi.org/10.1111/j.1523-5378.2007.00517.x   [Pubmed]       
 
23. Gisbert, JP., Bermejo, MF., Infante, JM., Gallardo, BP., Bermejo, AB., Rodri´guez, JM. et al. Levofloxacin, amoxicilline, and omeprazole as first-line triple therapy for Helicobacter pylori eradication. J Clin Gastroenterol. 2009; 43: 384-385. http://dx.doi.org/10.1097/MCG.0b013e31816d921c   [Pubmed]       
 
24. Molina-Infante J, Perez-Gallardo B, Fernandez-Bermejo M, Hernandez-Alonso M, Vinagre G, Duenas C, et al. Clinical trial: Clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2010; 31: 1077-1084.
 

How to Cite this Article
Pubmed Style

Telaku S, Manxhuka-Kerliu S, Kraja B, Qirjako G, Prifti S, Fejza H. The Efficacy of Levofloxacin-based Triple Therapy for First-line Helicobacter Pylori Eradication . Med Arh. 2013; 67(5): 348-350. doi:10.5455/medarh.2013.67.348-350



Web Style

Telaku S, Manxhuka-Kerliu S, Kraja B, Qirjako G, Prifti S, Fejza H. The Efficacy of Levofloxacin-based Triple Therapy for First-line Helicobacter Pylori Eradication . www.scopemed.org/?mno=46172 [Access: July 31, 2014]. doi:10.5455/medarh.2013.67.348-350



AMA (American Medical Association) Style

Telaku S, Manxhuka-Kerliu S, Kraja B, Qirjako G, Prifti S, Fejza H. The Efficacy of Levofloxacin-based Triple Therapy for First-line Helicobacter Pylori Eradication . Med Arh. 2013; 67(5): 348-350. doi:10.5455/medarh.2013.67.348-350



Vancouver/ICMJE Style

Telaku S, Manxhuka-Kerliu S, Kraja B, Qirjako G, Prifti S, Fejza H. The Efficacy of Levofloxacin-based Triple Therapy for First-line Helicobacter Pylori Eradication . Med Arh. (2013), [cited July 31, 2014]; 67(5): 348-350. doi:10.5455/medarh.2013.67.348-350



Harvard Style

Telaku, S., Manxhuka-Kerliu, S., Kraja, B., Qirjako, G., Prifti, S. & Fejza, H. (2013) The Efficacy of Levofloxacin-based Triple Therapy for First-line Helicobacter Pylori Eradication . Med Arh, 67 (5), 348-350. doi:10.5455/medarh.2013.67.348-350



Turabian Style

Telaku, Skender, Suzana Manxhuka-Kerliu, Bledar Kraja, Gentiana Qirjako, Skerdi Prifti, and Hajrullah Fejza. 2013. The Efficacy of Levofloxacin-based Triple Therapy for First-line Helicobacter Pylori Eradication . Medical Archives, 67 (5), 348-350. doi:10.5455/medarh.2013.67.348-350



Chicago Style

Telaku, Skender, Suzana Manxhuka-Kerliu, Bledar Kraja, Gentiana Qirjako, Skerdi Prifti, and Hajrullah Fejza. "The Efficacy of Levofloxacin-based Triple Therapy for First-line Helicobacter Pylori Eradication ." Medical Archives 67 (2013), 348-350. doi:10.5455/medarh.2013.67.348-350



MLA (The Modern Language Association) Style

Telaku, Skender, Suzana Manxhuka-Kerliu, Bledar Kraja, Gentiana Qirjako, Skerdi Prifti, and Hajrullah Fejza. "The Efficacy of Levofloxacin-based Triple Therapy for First-line Helicobacter Pylori Eradication ." Medical Archives 67.5 (2013), 348-350. Print. doi:10.5455/medarh.2013.67.348-350



APA (American Psychological Association) Style

Telaku, S., Manxhuka-Kerliu, S., Kraja, B., Qirjako, G., Prifti, S. & Fejza, H. (2013) The Efficacy of Levofloxacin-based Triple Therapy for First-line Helicobacter Pylori Eradication . Medical Archives, 67 (5), 348-350. doi:10.5455/medarh.2013.67.348-350







Total Download: 164.951
(for Medical Archives)
Total Submission during last 24 hours: 166


» For Authors




Become Reviewer


» Login Area




Follow ScopeMed on Twitter

ScopeMed Home | About ScopeMed | Contact Us | Terms & Conditions | Privacy Policy
The articles in Scopemed are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Service of SAGEYA Publishing for Scientific Publications. Copyright © ScopeMed® International Medical Journal Management and Indexing System.